Review Reports
- Nicole Brighi1,
- Alberto Farolfi1,* and
- Vincenza Conteduca1
- et al.
Reviewer 1: Anonymous Reviewer 2: Sang-We Kim
Round 1
Reviewer 1 Report
The authors extensively review the issue of immunotherapy in renal cell carcinoma. The manuscript is well written and well organized.
I would suggest to add a table summarizing the several clones of PD-L1 with the different cut-off used in each study mentioned by the authors. This would help a better undestanding of the usefulness of PD-L1 as predictive marker.
I would suggest to add a paragraph discussing the role of immunotherapy in the main histotypes.
Author Response
Please see the attachment.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Well written review.
The authors discussed the inflammation in the aspect of prognostic or predictive aspect. Because there are drugs for inflammation such as NSAIDS or anti-IL-1b (canakinumab). Is it possible to comment on the role of these agents for the treatment of RCC?
Author Response
Please see the attachment.
Author Response File: Author Response.pdf